* Please kindly note that our products and services can only be used to support research purposes (Not for clinical use).
At Creative Peptides, we can customize highly active peptide inhibitors to meet your project needs.
Due to their advantages of low toxicity, easy synthesis, rapid elimination, and fewer side effects, peptide inhibitors have been a very attractive approach in the treatment of many diseases such as cancer, AIDS, nervous system diseases, etc.
These approaches of synthesizing peptide inhibitors not only enhance the inhibitory activity on protein-protein interactions but also enhance the pharmacokinetic properties.
Based on more than ten years of successful peptide synthesis experience and extensive professional knowledge, Creative Peptides provides customized peptide inhibitors synthesis service for peptide-drug development companies and academic institutions, to promote effective cancer therapy methods development. Our scientists are proficient in the latest methods of peptide inhibitor synthesis. We ensure timely delivery of high-quality products.
Your inquiry should be resolved within 48 hours after receiving the request. We will provide the price and lead time of the project. Even if the project may require more work than expected, Creative Peptides will still base its quotation. For the failure of synthesis, we will not charge customers.
We also have some peptide inhibitors in stock.
Creative Peptides has accumulated a huge library of peptide knowledge including frontier peptide articles, application of peptides, useful tools, and more!
Vasoconstrictor substances, such as norepinephrine and epinephrine, have been mingled with local anesthetics to ...
Delmitide, also known as RDP58, is a novel D-amino acid decapeptide with anti-inflammatory effect. RDP58 is a te ...
Octreotide, a long-acting structural derivative of somatostatins, is a synthetic peptide analog of somatostatin with the same ...
MEN 10376 (Asp-Tyr-D-Trp-Val-D-Trp-D-Trp-Lys-NH2) is an analogue of Neurokinin A (NKA), which has a selective af ...
The voltage-gated Kv1.3 channel in effector memory T cells serves as a new therapeutic target for multiple scler ...